Penumbra Inc. (PEN)

NYSE: PEN · Real-Time Price · USD

291.72

-1.12 (-0.38%)

At close: May 01, 2025, 11:52 AM

-0.38% (1D)

Bid	291.36
Market Cap	11.3B
Revenue (ttm)	1.24B
Net Income (ttm)	42.23M
EPS (ttm)	1.07
PE Ratio (ttm)	272.64
Forward PE	59.41
Analyst	Buy

Ask	292.02
Volume	220,372
Avg. Volume (20D)	510,490
Open	293.49
Previous Close	292.84
Day's Range	291.09 - 299.55
52-Week Range	148.00 - 310.00
Beta	0.56

About PEN

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling...

[Read more]

Industry Medical - Devices

Sector Healthcare

IPO Date Sep 18, 2015

Employees 4,500

Stock Exchange NYSE

Ticker Symbol PEN

Website https://www.penumbrainc.com

Full Company Profile

Analyst Forecast

According to 16 analyst ratings, the average rating for PEN stock is "Buy." The 12-month stock price forecast is $318, which is an increase of 9.01% from the latest price.

Stock Forecasts

Earnings Surprise

Penumbra has released their quartely earnings on Apr 23, 2025:

Revenue of $324.14M exceeds estimates by $8.49M, with 16.32% YoY growth.

EPS of 0.83 exceeds estimates by 0.16, with 102.44% YoY growth.

Why Price Moved

1 week ago

+6.99%

Penumbra shares are trading higher after the compa... Unlock content with Pro Subscription

1 month ago

+4.6%

Penumbra shares are trading higher after B of A Securities initiated coverage on the stock with a Buy rating and announced a price target of $320.

News

2 days ago · seekingalpha.com

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...

1 day ago · zacks.com

Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

3 days ago · zacks.com

3 Reasons Growth Investors Will Love Penumbra (PEN)

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

2 days ago · zacks.com

Why Penumbra (PEN) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 week ago · benzinga.com

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

Penumbra Inc PEN stock is trading higher after the company reported better-than-expected first-quarter 2025 earnings and reaffirmed the 2025 forecast.

1 week ago · zacks.com

Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand

PEN reports better-than-expected earnings and revenues in the first quarter of 2025.

1 week ago · seekingalpha.com

Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript

Penumbra, Inc. (NYSE:PEN ) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen - CFO ...

1 week ago · zacks.com

Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate...

1 week ago · zacks.com

Penumbra (PEN) Q1 Earnings and Revenues Top Estimates

Penumbra (PEN) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.41 per share a year ago.

1 week ago · zacks.com

Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again

Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Load More News